Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.37−0.03 (-7.82%)
Close on Nov 17, 2026Market cap $1.29MP/E –Yield –
Scinai Immunotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Scinai Immunotherapeutics's R&D Expenses for the twelve months ending Dec 31, 2021 was $3.25M. For fiscal 2025 it was $2.37M, down 57.2% from the year before. The highest annual figure on record is $16.01M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37M | -57.2% |
| FY2024 | Dec 31, 2024 | $5.53M | +6.2% |
| FY2023 | Dec 31, 2023 | $5.21M | -9.6% |
| FY2022 | Dec 31, 2022 | $5.77M | +77.4% |
| FY2021 | Dec 31, 2021 | $3.25M | -79.7% |
| FY2020 | Dec 31, 2020 | $16.01M | +195.6% |
| FY2017 | Dec 31, 2017 | $5.42M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | $1.45M | +23.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.00M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.97M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.16M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.18M | – |
See a number that looks wrong?